Preferred Label : Lutetium-177;

MeSH synonym : Lu-177 radioisotope; 177Lu radioisotope;

UNII : BRH40Y9V1Q;

Details


Keyword's position in hierarchy(ies) : arborescence

Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/theralugand
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Lutetium (177Lu) chloride
Lutetium-177
Radioisotopic Labeling
drug approval
europe
risk management
Precursor Radiopharmaceutical Dosage Form

---
https://www.has-sante.fr/jcms/p_3518264/fr/lunca-chlorure-de-lutetium-177lu-precurseur-radiopharmaceutique
2024
false
false
false
France
insurance, health, reimbursement
Radioisotopic Labeling
evaluation of the transparency committee
Precursor Radiopharmaceutical Dosage Form
Lutetium-177
radiopharmaceuticals
lutetium
chlorides

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
radiopharmaceuticals
Lutetium Lu 177 Vipivotide Tetraxetan
Lutetium Lu 177 Vipivotide Tetraxetan
lutetium (177Lu) vipivotide tetraxetan
radiopharmaceuticals
radiopharmaceuticals
Lutetium-177
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
PSMA-Positive Tumor
antineoplastic combined chemotherapy protocols
injections, intravenous
infusions, intravenous
FOLH1 protein, human
product surveillance, postmarketing
pregnancy
breast feeding

---
https://www.has-sante.fr/jcms/p_3434491/fr/endolucin-beta-chlorure-de-lutetium-177-lu-no-carrier-added-n-c-a-precurseur-radiopharmaceutique
2023
false
false
false
France
Radiopharmaceutical precursor (qualifier value)
Radioisotopic Labeling
insurance, health, reimbursement
evaluation of the transparency committee
Lutetium-177
lutetium

---
https://www.ema.europa.eu/en/medicines/human/EPAR/illuzyce
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Lutetium-177
Radioisotopic Labeling
drug approval
europe
neuroendocrine tumors
prostatic neoplasms
radiopharmaceuticals
other therapeutic radiopharmaceuticals
Precursor Radiopharmaceutical Solution Dosage Form

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.